Treatment of pediatric pulmonary hypertension by Hawkins, Amy & Tulloh, Robert
© 2009 Hawkins and Tulloh, publisher and licensee Dove Medical Press Ltd. This is an Open Access article   
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 509–524
Vascular Health and Risk Management
509
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Treatment of pediatric pulmonary hypertension
Amy Hawkins 
Robert Tulloh
Department of Congenital Heart 
Disease, Bristol Royal Hospital  
for Children, Bristol UK
Correspondence: Robert Tulloh 
Department of Congenital Heart Disease, 
Bristol Royal Hospital for Children, Upper 
Maudlin Street, Bristol BS2 8BJ, UK 
Tel +44 117 342 8856 
Fax +44 117 342 8857 
email robert.tulloh@uhbristol.nhs.uk
Abstract: Pulmonary hypertension was once thought to be a rare condition and only managed 
in specialized centers. Now however, with the advent of echocardiography, it is found in many 
clinical scenarios, in the neonate with chronic lung disease, in the acute setting in the intensive 
care unit, in connective tissue disease and in cardiology pre- and postoperatively. We have 
a better understanding of the pathological process and have a range of medication which is 
starting to be able to palliate this previously fatal condition. This review describes the areas 
that are known in this condition and those that are less familiar. The basic physiology behind 
pulmonary hypertension and pulmonary vascular disease is explained. The histopathologic 
process and the various diagnostic tools are described and are followed by the current and 
future therapy at our disposal.
Keywords: pulmonary hypertension, congenital heart disease, pulmonary vascular resistance, 
pulmonary vasodilators
Introduction
Pulmonary arterial hypertension (PAH) can be implicated in the morbidity and mortality 
of many areas of cardiac and noncardiac pathology, and is an important complication 
in many patients with congenital heart disease.1–3 Traditionally, a diagnosis of PAH 
was accompanied by a bleak prognosis, with the survival with “primary” pulmonary 
hypertension being only 2.8 years. However, in recent years, increased awareness 
of this condition combined with more effective intervention at an early stage has 
reduced the number of patients with advanced pulmonary vascular disease (PVD), 
and improved survival rates.1
Definition
Pulmonary arterial hypertension can be defined as an increase in pulmonary arterial 
pressure (PA pressure) in the pulmonary vascular bed,1 and is defined as a mean PA 
pressure of more than 25 mmHg at rest or 30 mmHg with exercise.2 However, in clinical 
practice, echocardiography is often used instead of cardiac catheterization, and thus 
pulmonary hypertension (PH) is more commonly considered to occur when systolic 
PA pressure  half systolic systemic pressure.3 This allows for age-related changes 
since a pressure of 30 mmHg in a 300 g baby has different implications to that in a 
70 kg adult. PA pressure is formed by a combination of pulmonary blood flow and 
pulmonary vascular resistance, known as a modification of Ohm’s law (V = I × R) or 
Darcy’s law.4 In the fetus, the pulmonary vascular resistance (PVR) is high, which 
maintains a high mean PA pressure and so blood is preferentially shunted from the Vascular Health and Risk Management 2009:5 510
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pulmonary artery to the systemic circulation via the arterial 
duct. Within a few days of birth, the PVR falls rapidly, 
leading to a consequent fall in PA pressure.5 However, if there 
is a disease process which falls to allow the PVR to fall or 
if there is a pathological increase in either pulmonary blood 
flow or pulmonary vascular resistance, pulmonary hyperten-
sion will be maintained or will recur at a later age.
Causes of pulmonary hypertension
As the Venice classification states,6 pulmonary hypertension 
can be divided into a number of causes, including pulmonary 
arterial hypertension, pulmonary venous hypertension, and 
pulmonary hypertension due to respiratory causes. This can 
be simplified for clinical practice in pediatrics (Table 1).3 
One of the main distinctions is between primary or idiopathic 
pulmonary arterial hypertension (IPAH), which is extremely 
rare in pediatric patients, and secondary pulmonary hyperten-
sion, which constitutes the remainder of the causes. Of these 
secondary causes, congenital heart disease with a large left to 
right shunt secondary to a VSD or AVSD and chronic lung 
disease are the most common after the first few days of life.3
Pathogenesis
The histopathologic changes seen in PH are characterized 
by a process of vascular remodeling, which varies somewhat 
depending on the etiology. This involves proliferation of 
smooth muscle cells into peripheral (usually nonmuscular) 
arteries,7 together with medial hypertrophy in normally 
muscular arteries. Impaired growth and loss of arterioles 
leads to a reduction in arterial density, and this is eventually 
accompanied by dilatation complexes, plexogenic lesions and 
fibroid necrosis.8 In turn, this leads to a process of luminal 
obliteration.9,10 It is generally accepted that the early stages 
of this are reversible and the later stages are not.
Clinical features
Many of the symptoms of pediatric PH are nonspecific, and 
clinical features may be subtle even in advanced disease.11 At 
birth, children commonly have cyanosis with hepatomegaly, an 
active right ventricle on palpation and a loud pulmonary second 
sound on auscultation.3 This persistent pulmonary hypertension 
of the newborn (PPHN) may be difficult to treat but is well 
recognized in neonatal units and may improve with therapy 
to allow discharge home. If IPAH is left untreated, the most 
common presenting symptom is breathlessness, and children 
frequently present with poor appetite, faltering growth, leth-
argy, tachypnea, tachycardia, and irritability.11,12 Symptomatic 
severity has been connected to prognosis, reinforcing the need 
for early diagnosis and management.13 The child with congenital 
heart disease and a post-tricuspid shunt is however completely 
different. They may present late (especially if they have upper 
airway obstruction as in Down’s syndrome) or may have inoper-
able or only partly palliated disease (such as pulmonary atresia 
with ventricular septal defect and aorto-pulmonary collateral 
arteries). Hence a systematic approach to investigation is 
required in order to identify those patients with PH.
Clinically, the severity of PH is assessed according 
to a modification of the New York Heart Association 
(NYHA)/World Health Organization (WHO) classification 
of functional capacity (Table 2).14
Table 1 Causes of pulmonary hypertension in pediatrics
Neonatal Persistent pulmonary hypertension (PPHN – idiopathic)
Bronchopulmonary dysplasia
infection, eg, Streptococcus
Structural disease, eg, congenital diaphragmatic hernia
Cardiac Left to right shunt, eg, VSD, AVSD, PDA, AP window
Transposition of the great arteries (even without VSD)
Obstructive lesions, eg, TAPVC, MS, HLHS, HOCM, DCM
Acquired Chronic hypoxia, eg, cystic fibrosis, high altitude
Scoliosis
Airway obstruction, eg, tonsillar hypertrophy, tracheal stenosis/malacia
Vasculitic, eg, Connective tissue disease, sickle cell.
idiopathic Sporadic 20% genetic in origin
Familial 60% genetic in origin
Abbreviations: ASD, atrial septal defect;   VSD, ventricular septal defect; AVSD, atrioventricular septal defect; PDA, persistent ductus arteriosus; AP, aorto-pulmonary; TAPVC, 
total anomalous pulmonary venous connection; MS, mitral stenosis; HLHS, hypoplastic left heart syndrome; HOCM, hypertrophic obstructive cardiomyopathy; DCM, dilated 
cardiomyopathy.Vascular Health and Risk Management 2009:5 511
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Diagnosis and investigation
A summary of the investigations recommended in the current 
British Cardiac Society (BCS) Guidelines15 is shown in 
Table 3.
A chest radiograph may show pulmonary oligemia, with 
pruning of peripheral vessels16 there may be right ventricular 
hypertrophy (RVH) on electrocardiogram (ECG), and a 
low partial pressure of oxygen (PaO2) on arterial blood gas 
measurement. Echocardiography is a useful and sensitive 
investigation to identify possible secondary causes of PAH 
(such as ASD [rarely], VSD or cardiomyopathy), to provide 
a numerical assessment of the tricuspid regurgitation (TR) 
jet, and to assess left ventricular (LV) function. However, 
the results of derived formulae from echocardiography are 
to some extent operator-dependent. For older children, a 
six-minute walk test (6MWT) is a standardized method for 
assessing exercise tolerance in children,17 and it correlates 
well with the WHO functional class system.
Cardiac catheterization remains the diagnostic gold 
standard for PH. Current UK guidelines state that right 
heart catheterization is essential in the investigation of new 
patients with suspected PH, and should be undertaken to 
Table 2 Functional classification of pulmonary hypertension
Class i Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity 
does not cause undue dyspnea or fatigue, chest pain or near syncope.
Class ii Patients with pulmonary hypertension resulting in slight limitation of physical activity.   They are comfortable at rest. 
Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
Class iii Patients with pulmonary hypertension resulting in marked limitation of physical activity.   They are comfortable at 
rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.
Class iV Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms.   These 
patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is 
increased by any physical activity.
Table 3 imaging investigations recommended for the assessment of PH
Investigation Comments
Chest radiography May show increase in cardiac chamber or PA size, hypoperfused areas of lung, and 
parenchymal lung disease.
eCG May demonstrate RVH.
echocardiography Screening tool of choice for PAH. Detects cardiac disease (congenital, myocardial, valvular, 
intra-cavity clot or tumor, pericardial effusion). Use of contrast may be helpful to identify shunts.
Cardiac catheterization Gold standard to define the extent of disease. PA pressures, PVR, cardiac output and 
oxygen saturations can be calculated accurately.   Acute pulmonary vasoreactivity studies 
may also be carried out.
6 minute walk test (6 MwT) Provides a functional assessment of exercise capacity and degree of limitation of activity.
Arterial blood gases, lung function tests May be useful, although in patients with iPAH the results of lung function tests may be 
normal.   A decline in PaO2 is typically seen.
Blood investigations essential to exclude connective tissue diseases or pulmonary hypertension secondary 
to systemic disease: routine biochemistry and hematology, thyroid function, autoimmune 
screen (including anti-centromere antibody, anti-SCL70 and U1 RNP, phospholipid 
antibodies).
CT pulmonary angiography (CTPA) Used to look for enlargement of pulmonary arteries, filling defects and webs in the arteries.
Ventilation perfusion scanning More sensitive for chronic pulmonary thromboembolism than CTPA but not helpful when 
there is underlying parenchymal lung disease.
High resolution lung CT May show parenchymal lung disease, mosaic perfusion (a sign of pulmonary vascular 
embolism or thrombosis but for which there are other causes such as air trapping), and 
features of pulmonary venous hypertension.
Cardiac MRi Good investigation for imaging the right ventricle. Helpful in delineating congenital heart 
defects, and the pulmonary circulation by angiography.
Abdominal ultrasound Used for investigation of liver disease and suspected portal hypertension.
Abbreviations: PA, pulmonary artery; RVH, right ventricular hypertrophy; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; iPAH, idiopathic 
pulmonary arterial hypertension.Vascular Health and Risk Management 2009:5 512
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assess specific and accurate measurements of PA pressure 
and PVR.15 Vasodilator testing with inhaled nitric oxide16 
or prostacyclin17 can also be carried out at the time of cath-
eterization to assess the degree of reversibility of PH. In 
recent years, magnetic resonance imaging (MRI) has enabled 
detailed visualization of cardiac anatomy and pulmonary 
blood flow,20 and may even be used to assess degree of vessel 
compliance.21
Control of pulmonary vascular 
resistance
There are a number of different pathways involved in the 
control of PVR, many of which are therapeutic targets in the 
management of PAH, and are therefore essential to an under-
standing of the management of this condition (Table 4).
Patients with PAH have increased levels of circulating 
endothelin-1.22,23 As well as causing vasoconstriction, 
endothelin-1 leads to smooth muscle and fibroblast proliferation 
via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 
Serotonin levels are also raised in PAH, which stimulates 
mitogenesis of vascular cells, and increased expression of the 
serotonin transporter is found in hypertensive arteries.25 Patients 
with severe PAH have a relative deficiency of vasodilator 
pathways; they produce less endogenous prostacyclin, have 
reduced nitrogen oxide synthase (NOS) expression, and 
reduced vasoactive intestinal peptide (VIP) in the lungs.26,27
Prevention of pediatric pulmonary 
hypertension
Despite the advent of more efficacious therapeutics, prevention 
of pediatric pulmonary hypertension remains a priority. 
Patients with congenital heart defects secondary to a left to 
right shunt lesion should undergo early surgery to prevent 
development of PVD. This is particularly crucial in those 
patients with an AVSD or VSD.28 Surgical and post-operative 
care is also crucial, and improvements in this area are likely 
to be a contributing factor in the declining incidence of post-
operative pulmonary hypertension in children following 
cardiac surgery.29 This involves adequate ventilation, chest 
physiotherapy, and, if necessary, antibiotics.
It is also essential to maintain good oxygenation, relatively 
low CO2 and pH towards the upper limit of normal, in order 
to reduce the PA pressure as much as possible. Consequently, 
the effectiveness of pulmonary vasodilatation will also be 
maximized. Use of sedation with fentanyl and clonidine 
should also be used as prophylaxis against pulmonary 
hypertensive crises.30
Treatment of pediatric pulmonary 
hypertension
Current guidelines recommend that patients with PH should 
be managed by an experienced multiprofessional team at 
a specialist centre, with appropriate expertise and support 
for children and their families. Long-term community care 
involving clinical nurse specialists is also beneficial.15
Response to treatment is less predictable in children, and 
therefore, close monitoring and rapid alteration of treatment 
as necessary is required in pediatric patients.15 Research has 
suggested that prompt medical treatment of PAH, even in 
patients with established disease and Eisenmenger’s syndrome, 
may reduce the need for lung transplantation.31 There are fewer 
therapeutic options currently available for patients with PH in 
comparison to those with PAH.
Initially, treatment of PH involves thorough investigation 
of potential underlying causes; treatment will thus be directed 
accordingly. For example, patients whose PAH is caused by 
upper airway obstruction might undergo adenotonsillectomy, 
and those with cystic fibrosis, asthma or bronchopulmonary 
dysplasia should be managed with the relevant therapeutics. 
Drugs with a propensity to cause vasoconstriction such 
Table 4 Summary of mechanisms in PHT
Agent Mechanism Outcome
Hypoventilation Not fully understood, due to hypoxia and hypercarbia Vasoconstriction
Nitric oxide  
Nitrates
increases guanylyl cyclase Vasodilation
Phosphodiesterase type V inhibitors Prevent cyclic GMP breakdown Vasodilation
endothelin A – receptor  
B – receptor
Vasoconstriction  
Vasodilation and anti-mitogenic
Prostanoids increase cyclic AMP Vasodilation and anti-mitogenic
Rho-Kinase inhibitors increase GMP effect Vasodilation
Serotonin antagonists 5HT transporter Vasodilation and anti-mitogenic
Abbreviations: GMP, guanosine monophosphate;  AMP, adenosine monophosphate.Vascular Health and Risk Management 2009:5 513
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as sympathomimmetic decongestants with α-adrenergic 
properties should be avoided in children with pulmonary 
hypertension.
It is important to note that UK guidelines differ from those 
in other parts of the world; the American College of Chest 
Physicians (ACCP) and the European Society of Cardiologists 
(ESC) suggest that those in NYHA class III or IV should be 
treated with a specific oral therapy.32,33
Recent guidelines have suggested a treatment algorithm 
for the management of pediatric PAH15 (Figure 1).
Treatment of acute disease
Children presenting with syncope, right heart failure 
or post-operative PAH must be diagnosed and treated 
promptly and safely.34 This may be in an inhaled form (see Nitric 
oxide, below), orally with sildenafil, intravenously (see 
Epoprostenol, below), or with hemodynamic support (see 
Extracorporeal membranous oxygenation, below).3
Oxygen
Good ventilation in the intensive care unit is essential (see 
Treatment of pediatric pulmonary hypertension, above), 
and oxygen therapy has been shown to be of benefit acutely 
for both hypoxic and nonhypoxic patients with PAH.15 
Additionally, some patients may benefit from the use of 
domiciliary nocturnal oxygen therapy, both acutely, and 
alongside maintenance therapy.35
Nitric oxide
Nitric oxide (NO) inhalation is currently among the first line 
treatments for post-operative pediatric pulmonary hypertension 
or in the child with acute severe new presentation of PAH 
being managed on the intensive care unit,36,37 as it reduces PA 
pressure rapidly.38 Inhaled NO therapy is also used acutely in 
persistent pulmonary hypertension of the newborn.39 The mode 
of action of NO is via the stimulation of guanylyl cyclase and 
hence increased production of cyclic guanylate monophosphate 
(cGMP) in pulmonary smooth muscle cells; this causes uptake 
of calcium into the sarcoplasmic reticulum, which then leads to 
muscle relaxation, reduced PA pressure and PVR, and hence 
increased oxygenation. Any NO absorbed from the lungs into 
the systemic circulation is quickly deactivated by combination 
with hemoglobin, minimising any effect on the systemic circu-
lation. Therefore, NO acts solely on the pulmonary vasculature, 
leaving systemic arterial pressure unaffected.40,41
Oxygenation index (OI) is a calculation combining 
fraction of inspired oxygen (FiO2), mean airway pressure and 
PaO2 as an indicator of degree of respiratory compromise;42 
OI of more than 25 is the usual indication for initiation of 
treatment with NO.43 Acutely, doses start at 20 parts per 
million (ppm),44 although post-operative PAH may be treated 
with doses as low as 3–10 ppm.45 Sustained high doses of NO 
may lead to methemoglobinemia,45,46 and acute withdrawal 
of treatment may precipitate rebound PAH.44 The latter may 
be avoided by the use of phosphodiesterase inhibitors (see 
below), prostacyclins (see below) or discontinuation of NO 
followed by resumption of treatment at half the dose.47 Despite 
this, there is no clear evidence that short-term use of NO 
causes significant cardiac and respiratory complications.48
NO administration has been shown to reduce the need for 
extracorporeal membrane oxygenation (ECMO) treatment 
in term or near term neonates with hypoxic respiratory 
failure.42 However, a recent Cochrane review found that there 
was no significant difference in short-term post-operative 
mortality or mean PA pressure with administration of inhaled 
NO compared to placebo or conventional management 
(hyperventilation, use of sodium bicarbonate, intravenous 
inotropes and vasodilatory agents, and sedatives).49 Current 
European guidance suggests that there is insufficient 
evidence at present to recommend the use of prophylactic 
post-operative inhaled NO in patients with congenital 
heart disease at risk of PAH.50 However, there is sufficient 
evidence to support a trial of NO therapy (with a starting 
dose of 20 ppm, increasing to 40 ppm if there is no response) 
in patients with significant peri-operative PAH.50 Treatment 
should be discontinued after 30 minutes if there has been no 
clinically significant response.
extracorporeal membrane oxygenation (eCMO)
The use of extracorporeal membrane oxygenation (ECMO) 
has been associated with complications including interstitial 
and alveolar hemorrhage and secondary epithelial alterations.51 
For this reason, since the establishment of inhaled NO therapy 
as a treatment for pediatric PAH, the use of ECMO has 
significantly decreased.52 Despite this, there are still some 
incidences in which ECMO therapy is necessary, such as 
those infants with severe respiratory or cardiac disease in 
addition to pulmonary arterial hypertension; one study of chil-
dren with hypoxemic respiratory failure found that treatment 
with NO alone was successful in only 29% cases.53
Maintenance therapies
Aims of maintenance therapies for pediatric pulmonary 
hypertension will generally be to lower PA pressure in order 
to reduce or reverse the rate of progression of PVD, and 
thus to obtain functional improvement in terms of increased 
activity levels.Vascular Health and Risk Management 2009:5 514
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Current guidelines state that the choice of therapy 
should be based on WHO functional class and response 
to vasodilator testing during cardiac catheterization.15 The 
age of the child is also an important factor, as several drugs 
used to treat adults are unsuitable for use in young children; 
subcutaneous treprostinil frequently causes significant pain, 
and unwell children may be unable to tolerate inhaled doses 
of iloprost every 2–3 hours.15
In the UK, current statistics suggest that only a minority 
of patients are responsive to vasoreactivity studies and 
Pulmonary arterial hypertension
Vasoreactivity study
Positive
Calcium
channel blocker
Bosentan
Prostanoids
Unstable WHO-III/IV
Epoprostenol
Notify
transplant
centre
Serial monitoring
Symptoms WHO-IV
progression of breathlessness
refractory heart failure
syncope
(If on calcium channel blockers: inadequate
response after several months of treatment)
Combination drug
therapy
Refer for
transplantation
Balloon atrial
septostomy
Stable WHO-II/III
Negative
Supportive therapy: anticoagulation, oxygen, lifestyle advice
Figure 1 Current British Cardiovascular Society (BCS) algorithm for the management of PAH in children.
Abbreviation: wHO, world Health Organization.Vascular Health and Risk Management 2009:5 515
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treatment with calcium channel antagonists (see below).15 
Therefore, the majority of children are treated with specific 
disease-targeted therapies, such as intravenous epoprostenol 
(the only drug for children tested in a placebo-controlled 
trial),54 bosentan,55 and sildenafil. Choice of drug is dependent 
upon a number of factors, including side effect profile, 
route of administration, patient preferences, and physician 
experience.33
Calcium channel antagonists
The calcium channel antagonist, nifedipine is one of the 
oldest agents used for PAH,56,57 and amlodipine has been 
suggested to be beneficial for IPAH.58 An initial trial of these 
agents should be carried out, and calcium channel antagonists 
should only be continued in those patients who demonstrate an 
adequate vasodilator response (defined by a decrease in mean 
PA pressure and PVR by 20%).59 These patients may need 
no further medication.56,58 However, calcium channel antago-
nists are only efficacious in 5%–10% of children and adults, 
whereas nonresponders demonstrate a continually rising PVR. 
Some patients may switch from being ‘responders’, demon-
strating a stable response to calcium channel blockers for a 
period of several years, to ‘nonresponders,’ who suddenly 
require additional medication.
Phosphodiesterase inhibitors
Sildenafil, a phosphodiesterase inhibitor, given orally, has 
been shown to be a potent and selective pulmonary vaso-
dilator.60 Sildenafil works by selectively inhibiting phos-
phodiesterase V (PDE V),61 which is responsible for cGMP 
breakdown in lung tissue. The resultant increase in cGMP 
leads to calcium-mediated relaxation of vascular smooth 
muscle. These effects on pulmonary vasculature appear to 
occur independently of the cause of PAH, suggesting a role 
in the management of IPAH.62
An initial small-scale pilot study suggested that sildenafil 
improves hemodynamics and exercise capacity in children 
with primary pulmonary hypertension and PAH secondary to 
congenital heart disease.63 Since then, research has suggested 
that sildenafil works by improving endothelial-dependent 
vasodilatation, and by reducing plasma concentrations of 
endothelin-1 and von Willebrand factor, mediating a fall 
in PA pressure and PVR.64 In IPAH and Eisenmenger’s 
syndrome, there are reduced levels of endothelial progenitor 
cells; sildenafil has been hypothesized to increase numbers 
of these cells in the long term, thereby reducing endothelial 
dysfunction.65 Another study found that patients with PAH 
secondary to congenital heart defects treated with sildenafil 
had improved exercise capacity, WHO functional class 
and hemodynamics.66 Similarly, Baharani and colleagues 
found that patients with CHD had significant improvements 
in six-minute walking distance (6-MWD) and systolic PA 
pressure when treated with sildenafil in comparison with 
placebo.67 Sildenafil has been suggested to improve mean PA 
pressure, PVR, and exercise tolerance in PAH.68 Research 
has suggested that there is a direct dose-response relation-
ship between sildenafil and exercise capacity, measured by 
6-MWD; one study observed a significant improvement in 
6-MWD in patients taking 50 mg sildenafil three times daily 
(tds) compared to 25 mg tds or 12.5 mg tds.69
Sildenafil has also been shown to work synergistically 
with NO, enhancing the efficacy of exogenous NO, which 
further increases vasodilatation.70 This combined approach 
enables transfer of patients from intensive care, and facili-
tates weaning from high doses of nitric oxide, by reducing 
the rebound effect commonly seen with discontinuation of 
inhaled NO.18,71 In the long-term, sildenafil demonstrates 
marked down-regulatory responses which may limit its 
use,67 although this may be lessened when administered 
alongside NO. Side-effects of sildenafil may include nausea, 
abdominal discomfort, headache, dizziness and flushing72 and 
potentially, in the long-term, memory loss.73
More recently, research has suggested that another PDE 
type 5 inhibitor, vardenafil, may be more effective than silde-
nafil in vitro.74,75 These studies have suggested that vardenafil 
acts directly to reduce calcium influx in the pulmonary artery, 
in addition to its vasodilatory effects via cGMP.
endothelin receptor antagonists
Endothelin 1 (ET-1) acts on ETA and ETB receptors to 
promote mitosis of pulmonary artery smooth muscle cells; 
activation of ETA and ETB on smooth muscle cells causes 
vasoconstriction, whereas activation of ETB on the endothe-
lial cell releasing NO causes vasodilatation. This is thought 
to contribute significantly to the imbalance between vaso-
dilatation and vasoconstriction in pulmonary hypertension76 
and high levels of ET-1 have been found in the lung and 
circulation of patients with PAH.77,78
Bosentan, a nonselective (endothelin receptor A and B) 
antagonist has been shown to reduce mean PA pressure and 
PVR, and increase quality of life in patients with IPAH.17 One 
study found that in pediatric patients with congenital heart 
disease or connective tissue disease, treatment with bosentan 
for a median period of 14 months improved WHO functional 
class in 46%.79 Bosentan has also been found to be effective in 
patients with Eisenmenger’s syndrome, reducing PA pressure Vascular Health and Risk Management 2009:5 516
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and PVR and improving exercise capacity, without reducing 
oxygen saturations (the BREATHE-5 trial).80,81 However, 
bosentan has been shown to cause hepatic dysfunction 
in some patients; a recent study identified deranged liver 
function tests in 2.7% of children under 12 years of age 
on bosentan therapy, compared to 7.8% of those aged 
over 12 years.82 There is some evidence to suggest that in 
the long-term, there is a progressive decline in the beneficial 
treatment effects of bosentan, particularly in children.83
Sitaxsentan, a more ETA selective ERA has been investi-
gated in recent trials. Research has suggested that that it may 
play an important role in the management of PAH associ-
ated with connective tissue diseases, and it may have a more 
prolonged action than bosentan in children with congenital 
heart disease.84,85 One study of 247 patients found that use of 
sitaxsentan 100 mg once daily improved exercise capacity and 
WHO functional class in adult patients with PAH, and it has 
reduced hepatic toxicity compared to bosentan.86 As well as 
bosentan, sitaxsentan has also been shown to be effective in 
patients with Eisenmenger’s syndrome.87 Data on the use of 
sitaxsentan is limited in children at the current time.
Ambrisentan, another selective ERA antagonist has 
recently been shown to improve exercise capacity in patients 
with PAH compared to placebo, and is well-tolerated.88
Prostacyclin agonists
Prostacyclin (PGI2) is an endogenous vasodilatory mediator 
in the pulmonary vasculature; prostacyclin agonists act via 
cyclic AMP-dependent pathways in smooth muscle cells. Its 
effects include reducing PVR, inhibiting platelet aggregation, 
and reducing smooth muscle cell proliferation. In patients 
with pulmonary hypertension, pulmonary endothelial cells 
have decreased expression of prostacyclin synthase89 and 
urinalysis demonstrates a decrease in stable prostacyclin 
metabolites.26
Preliminary results of treatment with prostacyclins 
have been promising. Barst and colleagues90 found a 90% 
survival rate at four years for children with severe IPAH 
treated with prostacyclin, and studies have suggested that 
prostacyclins improve hemodynamic function and quality 
of life.91 Prostacyclins have been shown to work synergisti-
cally with NO, since they act through a different pathway 
and hence the therapeutic effects are additive. Therefore, 
these drugs may also be used when NO treatment has failed, 
when weaning from NO (as also occurs with sildenafil), or 
when therapeutic resistance has occurred.47,92 They may be 
administered intravenously (epoprostenol, treprostinil), by 
inhalation (iloprost) or orally (beraprost). However, the 
side-effects of prostacyclin agonists have limited their use 
to some extent; adverse events associated with epopros-
tenol include flushing, jaw pain, headaches, rashes and 
thrombocytopenia.93 Epoprostenol requires a continuous 
infusion and has a short half-life (6 minutes). Interruption 
of the infusion can lead to rapid increases in PVR, hemody-
namic collapse and death.93
Epoprostenol has been shown to improve the survival 
of patients with IPAH in the long-term,94 and is the gold 
standard starting treatment for patients with severe IPAH. It 
also has a role acutely in neonates with persistent pulmonary 
hypertension of the newborn (PPHN), post-operatively in 
children with heart disease, and in patients with IPAH, to 
reduce PVR prior to cardiac catheterization. However, epo-
prostenol has dose-limiting effects, and may cause severe 
rebound pulmonary arterial hypertension.95
Treprostinil was originally used as a subcutaneous 
infusion, which has a longer half-life and increased stability, 
so does not have to be kept in cooled storage.96 However, 
this route of administration is extremely painful, which 
has limited its use in the pediatric population. In recent 
research, intravenous preparations of treprostinil have 
been investigated, which have been suggested to cause 
fewer adverse effects than epoprostenol. However, whilst 
successful transfer rates have been achieved, high central-line 
infection rates were seen.97
Beraprost, an oral preparation, is well-tolerated and 
widely used in parts of Europe and in Japan, but research 
has suggested it is less efficacious than intravenous 
preparations.98,99
The inhaled form, iloprost, is easy to administer, has 
fewer side-effects as it acts directly on the lungs100 and it 
avoids the potential risks of infection seen with indwelling 
central lines.95 Iloprost must be administered approximately 
every two hours, and therefore has a greater role in the acute 
setting. It has been shown to be effective in improving 
hemodynamic parameters, exercise tolerance and quality of 
life in patients with PAH.101,102
Novel therapies
Rho-kinase inhibitors
Developments in recent years have suggested that a new class 
of drug, rho kinase inhibitors, may be beneficial in the treatment 
of pediatric PAH.103,104 Rho kinase causes vasoconstriction 
of vascular smooth muscle through phosphorylation and 
consequent inhibition of myosin phosphatase.105 It has 
also been shown that rho kinase acts by activation of the 
enzyme myosin light chain kinase (MLCK), which causes Vascular Health and Risk Management 2009:5 517
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phosphorylation of the hyper-constrictive segments of 
arteries in vitro.106 Animal models have suggested that activa-
tion of rho kinase is associated with pulmonary vasoconstric-
tion and proliferation, impaired endothelial vasodilatation 
and pulmonary remodelling, and that administration of its 
antagonists reverse these processes.107,108 Preliminary results 
have suggested that administration of intravenous fasudil, a 
selective rho-kinase inhibitor, may cause acute pulmonary 
vasodilatation and reduction in PA pressure in patients with 
severe PAH refractory to other therapies.103,109
Vasoactive intestinal peptide
Recent research investigating the role of vasoactive 
intestinal peptide (VIP) in rats has produced promising 
results.110 This study showed that ETA antagonists, ETB 
antagonists, and VIP all prevented the pulmonary vasocon-
striction caused by ET1. Unlike ETA and ETB antagonists, 
VIP did not induce an increase in airway resistance and 
thus this peptide may exert protective effects against both 
the vascular and bronchial adverse effects of ETI. This may 
therefore have a role in patients with PAH and co-existing 
chronic lung disease. Clearly therefore, in vivo experimenta-
tion is now needed.
estradiol derivatives
There has been limited investigation into the use of 
2-ethoxyestradiol, a nonestrogenic metabolite of estradiol in the 
treatment of PAH.111 This study found that 2-ethoxyestradiol 
lowered right ventricle (RV) peak systolic pressure and con-
sequently led to reduced vascular remodelling and mortality 
in rats with PAH. This suggests that in vitro anti-proliferative 
agents including synthetic analogues of estradiol metabolites 
may be protective against development of PVD.
Apoptosis and gene therapy
Limited research has suggested that modulation of the 
process of apoptosis (programmed cell death) involved 
in the process of vascular remodelling in PAH could be 
one possible therapeutic opportunity.112,113 For example, 
survivin (also known as Birc5), is one of a family of genes 
known to inhibit apoptosis; the use of molecular antagonists 
of survivin to increase cell death and prevent vascular 
remodelling may, in the future, hold therapeutic potential.114 
Similarly, preliminary research has suggested that the use of 
the 3-hydroxy-3-methyl-glutaryl-CoA (HMG CoA) reductase 
inhibitor, pravastatin, and the Cox-2 inhibitor, celecoxib, 
prevent the development of monocrotaline-induced PAH 
in rats.115,116 Simvastatin has been found to be ineffective in 
this respect in vitro.117
Serotonin pathways
Research has found that patients with PAH have increased 
plasma serotonin levels,118 and that over-expression of the 
serotonin transporter gene (SERT) increases PA pressure.119 
Hypoxia and monocrotaline-induced PAH in animals 
has been shown to be inhibited by the selective serotonin 
reuptake inhibitor (SSRI), fluoxetine.120,121 So far however, 
studies in humans have not produced statistically significant 
results.122
l-Arginine
An alternative approach to inhaled NO therapy is to increase 
endogenous NO synthesis. Plasma l-arginine is a substrate 
for endothelial nitrogen oxide synthase,123 and experimental124 
and clinical125 data have suggested that patients with 
a left-to-right shunt lesion may be deficient in l-arginine, both 
pre- and post-operatively. However, research has suggested 
that low levels of plasma arginine do not correlate with the 
degree of post-operative PAH126. Further trials are needed 
to ascertain whether peri-operative therapy with l-arginine 
may be beneficial.
Anticoagulation
Whilst most children with PAH will not be treated with 
anticoagulation, it is recommended that those at high risk of 
thromboembolism (such as patients with IPAH and reduced 
cardiac output, indwelling venoatrial shunt or severe poly-
cythemia), should be prescribed warfarin.127
Other therapies
Although rare, children with systemic sclerosis and 
coexisting pulmonary hypertension should be treated with 
corticosteroids, which appear to slow disease progression 
in this group.128
Combination treatment
Currently, there is some debate as to the optimal management 
of patients who demonstrate clinical deterioration despite 
maximal targeted therapy with one agent. The use of com-
bination therapies has been widely adopted across the US 
and Europe, but currently, there is little clear consensus as to 
the most effective and safe combinations.129 In Switzerland 
and other countries, combination therapies involving two or 
three of bosentan, iloprost, and sildenafil are commonly used 
but their relative merits are not yet clarified.130
Combination of sildenafil with an endothelin receptor 
antagonist (notably bosentan) has been recently validated 
in several trials, improving hemodynamic variables, 
exercise capacity, and quality of life in patients with IPAH Vascular Health and Risk Management 2009:5 518
Hawkins and Tulloh Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
or PAH unresponsive to monotherapy.131–133 Limited trials 
of treatment with bosentan and a prostacyclin agonist such 
as epoprostenol or iloprost have suggested this may be 
an effective combination.134,135 Inhaled prostacyclin and 
milrinone have also been postulated to work synergistically 
to reduce PVR.136
However, the pharmacokinetics involved are complex; at 
steady state, when used in combination, bosentan reduces the 
maximum plasma concentration of sildenafil, and sildenafil 
increases the concentration of bosentan.137 Further research 
is therefore needed to establish the clinical applications 
for these complex drug interactions. It is also important to 
note that dual treatments combine the adverse effects of 
both drugs, and thus the incidence of side-effects may be 
increased.138
Management of refractory pulmonary 
hypertension
Those patients who remain symptomatic despite medical 
therapies may require more invasive forms of management.
Atrial septostomy
Children with PAH and without adequate right to left 
shunting across the atria commonly develop recurrent 
syncopal episodes.12 Atrial septostomy, either by cardiac 
catheterization or surgically, has been shown to be beneficial 
in patients experiencing recurrent syncope, by creating a left 
to right shunt and consequently maintaining cardiac output.139 
In turn, this procedure has been suggested to reduce the signs 
and symptoms of right heart failure.141–144 Improved survival 
rates have also been demonstrated following atrial septos-
tomy; Kerstein and colleagues139 demonstrated increased 
survival at one and two years, 87% and 76%, respectively.
Lung transplantation
Lung transplantation is currently only considered as a last 
resort,145 in part due to concerns regarding long-term survival 
rates; one study found that survival rates were 77% at one year, 
62% at two years, and 55% after five years.146 Since 1986, 
over 1055 children have undergone transplantation world-
wide.147 Between January 1990 and June 2006, there were 977 
Table 5 Key trials of pharmacological agents for the management of pediatric PAH
First Author/year Official  
acronym
Number  
of patients
Active drug Comparator  Study period 
(weeks)
Outcome* (active drug 
versus comparator)
Rubin et al 1990150 – 23 epoprostenol Randomized controls 8 Net benefit
Barst et al 1996151 – 81 epoprostenol Randomized controls 12 Net benefit
Badesch et al 2000152 – 111 epoprostenol Randomized controls 12 Net benefit
Channick et al 2001153 – 32 Bosentan Placebo 12 Net benefit
Langleben et al 2002154 – 71 Terbogrel Placebo 12 Net harm
Simonneau et al 200296 – 470 Treprostinil Placebo 12 No difference
Galie et al 2002155 ALPHABeT 130 Beraprost Placebo 12 No difference
Olschewski et al 2002101 AiR 203 iloprost Placebo 12 Net benefit
Rubin et al 2002156 BReATHe-1 213 Bosentan Placebo 16 Net benefit
Barst et al 200399 – 116 Beraprost Placebo 36 Net benefit
Sastry et al 2004157 – 22 Sildenafil Placebo 12 Net benefit
Humbert et al 2004158 BReATHe-2 33 epoprostenol + bosentan epoprostenol + placebo 16 Net benefit
Barst et al 2004159 STRiDe-1 178 Sitaxsentan Placebo 12 Net harm
Galie et al 2005160 SUPeR-1 278 Sildenafil Placebo 12 No difference
wilkins et al 2005161 SeRAPH 26 Bosentan Sildenafil 16 Net benefit
Singh et al 2006162 – 20 Sildenafil Placebo 8 Net benefit
Galie et al 200680 BReATHe-5 20 Sildenafil Placebo 8 Net benefit
Barst et al 2006163 STRiDe-2 185 Sitaxsentan Placebo 18 Net benefit
McLaughlin et al 2006164 STeP 67 inhaled iloprost Placebo 12 Net benefit
Hoeper et al 2006165 COMBi 40 inhaled iloprost Placebo 12 Net benefit
Galie et al 200888 ARieS 394 Ambrisentan Placebo 12 No difference
Galie et al 2008148 eARLY 185 Bosentan Placebo 12 Net benefit
Simonneau et al 2008138 PACeS 267 Sildenafil Placebo 16 Net benefit
Notes: *The outcome variables are risk of death or hospitalization due to complications of PH.
Abbreviations: PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.Vascular Health and Risk Management 2009:5 519
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pediatric lung transplantation; of these, the primary indication in 
104 patients (10.6%) was IPAH, 34 (3.5%) due to CHD, 18 for 
PVD (1.8%), and 17 (1.7%) for Eisenmenger’s syndrome.147 
However, the use of lung transplantations is restricted by 
waiting times, risks of surgery, and the problems accompanying 
transplant rejection, and thus cannot be considered as a viable 
treatment option earlier in the course of disease.
Treatment outcomes and prognosis
Currently, there is no PAH-specific quality of life measure, 
although recent studies of outcomes in pediatric patients 
suggest that although physical activity is limited to approxi-
mately 50% of normal, psychological scores are 80%–90% 
of normal.147,148 These scores do not correlate with age, time 
since diagnosis, PVR or cause of PAH.
Treatment with disease-targeted therapies for secondary 
and idiopathic PAH has been shown to improve survival 
in a number of studies;15,129 a number of recent trials have 
investigated the relative efficacy of management options in 
pulmonary arterial hypertension (Table 5).149
A recent meta-analysis of trials of modern treatment 
modalities including phosphodiesterase inhibitors, endothelin 
receptor antagonists and prostacyclin agonists found that 
overall, active treatment resulted in reduction in mortality of 
43% (risk ratio 0.57, 95% confidence interval [CI] 0.35–0.92; 
p = 0.023) (Figure 2).149
Survival rates are typically higher in those with secondary 
PAH compared to IPAH, and for those with IPAH, combination 
therapy is more effective than monotherapy.141,166 Children with 
postoperative PAH have previously had particularly poor out-
comes, and therefore early detection in these patients is crucial.15 
There is currently limited evidence regarding the optimal 
management of patients with pulmonary venous hypertension, 
and for patients with other forms of pulmonary hypertension.
Conclusion
Advances in available therapeutics for pulmonary 
hypertension have improved survival in pediatric patients. 
General supportive care, early diagnosis and prompt 
surgery for patients with PAH secondary to CHD is crucial. 
Study %
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An individualized approach must be taken in deciding 
treatment options, depending on the symptoms, clinical 
signs, and hemodynamic status of each patient.
Following this, treatment options are complex and current 
BCS guidelines suggest that treatment should universally depend 
upon the NYHA functional class and response to vasodilator 
therapy.15 Acutely, treatment options include oxygen therapy, 
NO and ECMO. Current maintenance therapies include calcium 
channel antagonists, phosphodiesterase inhibitors, endothelin 
receptor antagonists and prostacyclin agonists, with or without 
anticoagulation. For patients who remain symptomatic or whom 
demonstrate equivocal hemodynamic response to therapy with 
a single agent, combination therapy may be considered. Atrial 
septostomy and lung transplantation are generally considered 
as the next stage in patients who have been unresponsive to 
medical therapy. A recent systematic review of oral treatment 
methods in PAH highlighted the problems of small sample size 
and limited follow-up period in many of the available studies 
this is particularly problematic in pediatric populations.167 More 
in vivo research is needed to assess the efficacy of the increasing 
number of novel therapies.
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